Market Overview

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

Share:
Related BMY
Why A Bristol-Myers Squibb Bid On Celgene Is Plausible
Benzinga's Top Upgrades
Bristol-Myers presents data on daclatasvir at Liver Meeting (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Bristol-Myers Squibb Co. closed on Thursday at $46.17.

Latest Ratings for BMY

DateFirmActionFromTo
Apr 2015Morgan StanleyUpgradesEqual-weightOverweight
Mar 2015Leerink SwannMaintainsOutperform
Mar 2015JP MorganMaintainsOverweight

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...